Document is current
Any future updates will be listed below
-
Authors
Jurmeister, Philipp https://orcid.org/0000-0001-7745-3794
Flach, Susanne
Bergmayr, Linda
Schleich, Konstanze
Chimal Calderon, Edgar https://orcid.org/0009-0004-4559-0726
H Mochmann, Liliana https://orcid.org/0000-0002-6960-748X
Zhdanovich, Yauheniya
Klingler, Doreen
Pusztai, Ada
Kübler, Anna https://orcid.org/0009-0001-3368-6497
Walz, Christoph https://orcid.org/0009-0005-6284-6153
Westphalen, Christoph Benedikt
Beck, Alexander
Leitheiser, Maximilian
Breimer, Gerben E https://orcid.org/0000-0003-0365-3667
Rijken, Johannes A
Devriese, Lot
Baumeister, Philipp https://orcid.org/0000-0003-2759-4737
Skálová, Alena
Schallenberg, Simon
Klauschen, Frederick
Mock, Andreas https://orcid.org/0000-0002-3332-9166
-
Funding
Funding for this research was provided by:
LMU | Medizinischen Fakultät, Ludwig-Maximilians-Universität München
Deutsche Krebshilfe
- License Information
-
More Information
Article History
Received: 6 January 2026
Revised: 15 April 2026
Accepted: 16 April 2026
First Online: 2 May 2026
Disclosure and competing interests statement
: CBW served as an advisor for Astra Zeneca, Daiichi Sankyo, BMS, Frankfurt Institute of Clinical Cancer Research (IKF), Incyte, Johnson & Johnson, Roche, Taiho, received honoraria from Amgen, Astra Zeneca, Bayer, BMS, Daiichi Sankyo, GSK, Johnson & Johnson, Lilly, MSD, Merck, Pierre Fabre, QuIP GmbH, Roche, Servier, received travel support from Astra Zeneca, Daiichi Sankyo, Bayer, Johnson & Johnson, Roche, Servier, Taiho, received research funding from Roche (institutional), serves as an officer for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH) and Arbeitsgemeinschaft internistische Onkologie (AIO) and is a member of the EU Commission expert group: Mission Board for cancer and of the BMFTR steering committee: Strategiekreis Dekade gegen Krebs. The remaining authors declare no competing interests.
